
This episode features Dave, the CEO of Eli Lilly, discussing the pharmaceutical company's leadership in the GLP-1 drug market. Topics include the rise of GLP-1 drugs, Eli Lilly's market capitalization increase, and the development of a pill alternative to injections.
Dave highlights the significant growth of Eli Lilly, noting an 860% increase in market capitalization since he became CEO. He mentions the stock price surge of over 1,000%, reflecting the company's success in the pharmaceutical industry.
The conversation emphasizes the importance of advancing science, whether through internal or external efforts. Dave expresses his enthusiasm for the podcast and the opportunity to share insights about Eli Lilly's innovations.
Dave, CEO of Eli Lilly, discusses GLP-1 drugs and the company's growth in the pharmaceutical market.

Eli Liy coming to save us here.🚨 All-In Summit Speaker Announcement: Dave Ricks
It's everyone's job to move the science.🚨 All-In Summit Speaker Announcement: Dave Ricks